Related Experiment Video
Updated: Jan 8, 2026
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
Improved adhesion and function of Pediococcus pentosaceus Li05 for acute colitis through surface modification.
Shengyi Han1,2, Kaicen Wang1, Kunkai Su3
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.
Conjugating MUC2 antibodies to Pediococcus pentosaceus Li05 (M-Li05) probiotics significantly enhanced their gastrointestinal adhesion and colonization. This improved probiotic therapy shows promise for treating colitis by reducing inflammation and pathogen load.
Area of Science:
- Microbiology
- Gastroenterology
- Biotechnology
Background:
- Probiotics are utilized for disease prevention and treatment, but their efficacy depends on gastrointestinal adhesion and colonization.
- Pediococcus pentosaceus Li05 exhibits anti-inflammatory properties, yet its therapeutic application is limited by poor mucoadhesion.
- Enhancing probiotic mucoadhesion is crucial for improving their therapeutic potential in the gut.
Purpose of the Study:
- To improve the mucoadhesive properties of Pediococcus pentosaceus Li05 by conjugating MUC2 antibodies.
- To evaluate the enhanced adhesion, colonization resistance, and therapeutic efficacy of M-Li05 in preclinical models of colitis.
Main Methods:
- Conjugation of MUC2 antibody to Pediococcus pentosaceus Li05 to create M-Li05.
- In vitro assessment of adhesion and colonization resistance.
- In vivo competitive adhesion assays in mice challenged with Citrobacter rodentium.
- Evaluation of M-Li05 efficacy in Citrobacter rodentium-infected and DSS-induced colitis mouse models, assessing histological injury, inflammation, and pathogen colonization.
Main Results:
- M-Li05 demonstrated significantly improved in vitro adhesion and colonization resistance compared to unmodified Li05.
- In vivo studies showed M-Li05 outcompeted Citrobacter rodentium colonization more effectively than Li05.
- M-Li05 treatment significantly reduced colonic histological damage, alleviated inflammation, and decreased pathogen colonization in colitis models.
Conclusions:
- Surface modification of Pediococcus pentosaceus Li05 with MUC2 antibodies (M-Li05) enhances its mucoadhesive and colonization capabilities.
- M-Li05 exhibits significant therapeutic potential in reducing inflammation and pathology associated with colitis.
- Engineered probiotics like M-Li05 represent a promising strategy for developing novel therapeutic interventions for inflammatory bowel diseases.
